$NMRA

Neumora Therapeutics, Inc.

CIK:0001885522|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 29,283	$ 38,724	$ 67,881	$ 90,875
General and administrative	12,907	15,316	27,173	34,101
Total operating expenses	42,190	54,040	95,054	124,976
Loss from operations	(42,190)	(54,040)	(95,054)	(124,976)
Other income (expense):
Interest income	935	2,250	2,166	5,324
Interest expense	(1,820)	(436)	(3,674)	(436)
Other income (expense), net	(7)	(480)	52	(505)
Total other income (expense)	(892)	1,334	(1,456)	4,383
Net loss before income taxes	(43,082)	(52,706)	(96,510)	(120,593)
Provision for income taxes	0	25	30	130
Net loss	(43,082)	(52,731)	(96,540)	(120,723)
Other comprehensive loss:
Unrealized loss on marketable debt securities	0	(12)	0	(77)
Comprehensive loss	$ (43,082)	$ (52,743)	$ (96,540)	$ (120,800)
Net loss per share, basic	$ (0.23)	$ (0.33)	$ (0.53)	$ (0.75)
Net loss per share, diluted	$ (0.23)	$ (0.33)	$ (0.53)	$ (0.75)
Weighted-average shares outstanding, basic	185,163	161,691	182,504	161,572
Weighted-average shares outstanding, diluted	185,163	161,691	182,504	161,572

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities:
Net loss	$ (96,540)	$ (120,723)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	14,589	16,489
Non-cash operating lease expense	120	1,777
Depreciation and amortization	15	176
Net accretion of investments in marketable securities	0	(2,185)
Impairment of held for sale assets	0	378
Loss (Gain) on disposal of property and equipment	(71)	62
Amortization of debt issuance costs and accretion of final payment fee	812	303
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(32)	1,111
Accounts payable	769	(2,663)
Accrued liabilities	(5,456)	(4,650)
Operating lease liabilities	(138)	(1,873)
Other assets		(54)
Net cash used in operating activities	(85,932)	(111,852)
Investing activities:
Purchases of marketable securities	0	(82,868)
Proceeds from maturities of marketable securities	0	157,341
Proceeds from sale of equipment	71	84
Net cash provided by investing activities	71	74,557
Financing activities:
Proceeds from term loan, net	0	18,398
Payment of debt issuance costs in connection with term loan amendment	(445)	0
Proceeds from employee stock purchase plan purchases	239	59
Proceeds from issuance of common stock in at-the-market transactions, net of commission and offering costs	20,371	0
Net cash provided by financing activities	20,165	18,457
Net change in cash and cash equivalents	(65,696)	(18,838)
Cash and cash equivalents and restricted cash at beginning of year	182,530	143,361
Cash and cash equivalents at end of period	116,834	124,523
Supplemental disclosure of cash flow information:
Cash paid for interest	1,458	134
Cash paid for income taxes	30	0
Supplemental disclosure of noncash investing and financing activities:
Principal amount of debt extinguished upon conversion to common stock	2,050	0
Debt issuance costs reclassified to equity in connection with conversion	63	0
Right-of-use-asset in connection with new operating lease agreement	0	532
Operating lease liability in connection with new lease agreement	$ 0	$ 505

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 116,834	$ 182,530
Prepaid expenses and other current assets	8,040	8,007
Total current assets	124,874	190,537
Property and equipment, net	25	40
Operating lease right-of-use assets	297	417
Other assets	53	53
Total assets	125,249	191,047
Current liabilities:
Accounts payable	4,147	3,379
Accrued liabilities	23,331	28,788
Operating lease liabilities, current portion	299	284
Total current liabilities	27,777	32,451
Long term debt, net	52,912	54,532
Operating lease liabilities, noncurrent	41	193
Total liabilities	80,730	87,176
Commitments and contingencies
Stockholders' equity:
Common stock	19	17
Additional paid-in capital	1,325,189	1,288,003
Accumulated deficit	(1,280,689)	(1,184,149)
Total stockholders' equity	44,519	103,871
Total liabilities and stockholders' equity	$ 125,249	$ 191,047